Tahlil

Pirüvat Kinaz (PK)

Sanal Hastane||1 dk okuma
Pirüvat Kinaz (PK)

Klinik kullanımı

Akut lösemilerde, sitopenilerde, anemilerde ve aplazilerde de eritrosit içi piruvat kinaz aktivitesi düşer. Prüvat kinaz eksikliği olanlarda yeni doğanın hemolitik hastalığı sık görülür.

Referans aralığı

60-220 μu/milyar eritrosit

 

 

#Akut lösemi#Anemi#aplazi#sitopenil#yeni doğanın hemolitik hastalığı

Kaynaklar ve Referanslar

  1. [1]Jia J, Luo Y, Zhong X, et al. “Methicillin-Resistant Staphylococcus Aureus (MRSA) Pyruvate Kinase (PK) Inhibitors and their Antimicrobial Activities.”. Current medicinal chemistry. 2022. PMID: 33749550. PubMed →
  2. [2]Doeven T, Glenthøj A, et al.. “Pyruvate kinase activators in hereditary haemolytic anaemias: current evidence and clinical potential”. Lancet. 2026. PMID: 41833294. PubMed →
  3. [3]Miwa S, Fujii H. “Pyruvate kinase deficiency.”. Clinical biochemistry. 1990. PMID: 2197027. PubMed →
  4. [4]Ahmed SH, Qadar LT, et al.. “Efficacy and safety of pyruvate kinase activator in treating hemolytic anemias: a systematic review”. Expert Review of Hematology. 2025. PMID: 40526104. PubMed →
  5. [5]Luke N, Hillier K, Al-Samkari H, et al. “Updates and advances in pyruvate kinase deficiency.”. Trends in molecular medicine. 2023. PMID: 36935283. PubMed →
  6. [6]King RA, Khoriaty R. “Hereditary disorders of ineffective erythropoiesis”. Blood Cells, Molecules & Diseases. 2025. PMID: 39938185. PubMed →
Paylaş:
← Tüm Makaleler